Tune in to learn how the recent FDA approval of lenacapavir (LEN) for PreP integrates into the current field of HIV prevention. Listen on the go or follow along with our expert-curated slides. Topics covered include: The current landscape of PrEPFDA approval of lenacapavirPhase III efficacy and safety data for lenacapavirRecommendations and perspectives on the future of PrEPPresenters:Colleen F. Kelley, MD, MPHProfessor of MedicineDivision of Infectious DiseasesDepartment of MedicineCo-Director, Emory Center for AIDS ResearchAssociated Dean for Research, Emory at GradyEmory University School of MedicineAtlanta, GeorgiaRaphael J. Landovitz, MD, MScProfessor of MedicineChief, Division of Infectious DiseasesAssociate Vice Chair for Clinical ResearchDepartment of MedicineDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, UCLA Center for Clinical AIDS Research & Education (CARE)Director, Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)Los Angeles, CaliforniaLink to full program: https://bit.ly/4m8RaOg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related